Fig. 1From: Monitoring therapeutic efficacy of sunitinib using [18F]FDG and [18F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinomaIn vivo therapy model follow-up. a-b Tumour volume evolution, as measured by calliper, for sets A and B of mice respectively (set A: n = 3 for control, n = 4 for treated/set B: n = 4 for each group). c-d Mice body weight evolution for sets A and B respectively. In all graphs, arrows indicate the first day of sunitinib treatmentBack to article page